Abstract
No public abstract is available from the verified source records.
Saroj Niraula, Ian F. Tannock
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Financial payments from drug manufacturers to oncologists and use of guideline-preferred cancer treatments
Kept as external metadata until matched
10.7326/m20-5665
10.7326/m20-5665
10.1634/theoncologist.2018-0423
10.1634/theoncologist.2018-0423
10.1001/jamainternmed.2018.0776
10.1001/jamainternmed.2018.0776
10.1001/jamainternmed.2016.2765
10.1001/jamainternmed.2016.2765
10.1001/jamahealthforum.2024.1581
10.1001/jamahealthforum.2024.1581
Unresolved referenced work
Kept as external metadata until matched
Conflicts of interest in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: Associations with recommendations
2020
10.1200/jco.2014.57.8898
10.1200/jco.2014.57.8898
10.1002/onco.13983
10.1002/onco.13983
10.1016/j.ejca.2026.116844
10.1016/j.ejca.2026.116844
10.1038/s41571-025-01073-3
10.1038/s41571-025-01073-3
10.1001/jama.2012.154
10.1001/jama.2012.154
10.1200/op-25-00695
10.1200/op-25-00695
No additional external references are available.